Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.74 |
| ▸ | FYN | P06241 | 4/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997123 | 0.91 | KDR (0.88) | KDRFYNFGFR2BRAFMAPK8 | |
| SCHEMBL4992158 | 0.90 | KDR (0.71) | KDRFYNFGFR2BRAFMAPK8 | |
| SCHEMBL4997553 | 0.86 | KDR (0.65) | KDRFYNFGFR2BRAFMAPK8 | |
| SCHEMBL4672616 | 0.85 | KDR (1.00) | KDRFGFR2BRAFCSNK2A2CSNK2B | |
| SCHEMBL4199241 | 0.84 | KDR (0.55) | KDRFYNBRAFMAPK8MAPK10 | |
| SCHEMBL2933512 | 0.83 | KDR (0.68) | KDRFYNFGFR2BRAFCCNT1 | |
| SCHEMBL2931471 | 0.80 | KDR (0.59) | KDRFYNFGFR2BRAF | |
| SCHEMBL2927120 | 0.77 | FYN (0.62) | KDRFYNFGFR2BRAFABL1 | |
| SCHEMBL1679230 | 0.77 | FYN (0.67) | KDRFYNMAP4K4ADORA2AADORA2B | |
| SCHEMBL4194415 | 0.76 | KDR (0.51) | KDRFYNMAPK8MAPK10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | claimed |
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | KDR 2202/4885FYN 20/4885FGFR2 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.